# Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Source: https://onco.cc/trials/nct06123754/  
OnCo record `nct06123754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection in non-small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.

## Summary

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC is a phase 3 interventional study registered as NCT06123754 by 3D Medicines (Sichuan) Co., Ltd., with 390 participants planned, started 2023-11-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection and placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06123754
- Phase: 3
- Setting: A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT06123754: https://clinicaltrials.gov/study/NCT06123754

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06123754.json